HUS2100011I1 - Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére - Google Patents

Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére

Info

Publication number
HUS2100011I1
HUS2100011I1 HUS2100011C HUS2100011C HUS2100011I1 HU S2100011 I1 HUS2100011 I1 HU S2100011I1 HU S2100011 C HUS2100011 C HU S2100011C HU S2100011 C HUS2100011 C HU S2100011C HU S2100011 I1 HUS2100011 I1 HU S2100011I1
Authority
HU
Hungary
Prior art keywords
methods
same
inflammatory diseases
treat inflammatory
selectin antibodies
Prior art date
Application number
HUS2100011C
Other languages
English (en)
Original Assignee
Novartis Pharma Ag
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Ag, Oklahoma Med Res Found filed Critical Novartis Pharma Ag
Publication of HUS2100011I1 publication Critical patent/HUS2100011I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUS2100011C 2006-12-01 2021-04-07 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére HUS2100011I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87217006P 2006-12-01 2006-12-01
EP13164403.1A EP2662091B1 (en) 2006-12-01 2007-11-30 Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases

Publications (1)

Publication Number Publication Date
HUS2100011I1 true HUS2100011I1 (hu) 2021-05-28

Family

ID=39492818

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE13164403A HUE041957T2 (hu) 2006-12-01 2007-11-30 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
HUS2100011C HUS2100011I1 (hu) 2006-12-01 2021-04-07 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
HUS2100015C HUS2100015I1 (hu) 2006-12-01 2021-04-23 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE13164403A HUE041957T2 (hu) 2006-12-01 2007-11-30 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2100015C HUS2100015I1 (hu) 2006-12-01 2021-04-23 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére

Country Status (11)

Country Link
US (2) US8377440B2 (hu)
EP (3) EP2097105A4 (hu)
CY (2) CY1121072T1 (hu)
DK (1) DK2662091T3 (hu)
ES (1) ES2699273T3 (hu)
HU (3) HUE041957T2 (hu)
LT (2) LT2662091T (hu)
PL (1) PL2662091T3 (hu)
PT (1) PT2662091T (hu)
SI (1) SI2662091T1 (hu)
WO (1) WO2008069999A2 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110212096A1 (en) * 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
EP2097105A4 (en) 2006-12-01 2010-09-15 Selexys Pharmaceuticals Corp ANTI-P-SELECTINE ANTIBODIES AND METHODS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
US8945565B2 (en) * 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
HUE037992T2 (hu) * 2010-12-21 2018-09-28 Selexys Pharmaceuticals Corp Anti-P-szelektin antitestek és eljárások azok alkalmazására és azonosítására
WO2015006501A2 (en) 2013-07-09 2015-01-15 President And Fellows Of Harvard College Microvessel endothelial cell surface markers and uses thereof
WO2015006500A2 (en) 2013-07-09 2015-01-15 President And Fellows Of Harvard College Endothelial cell genes and uses thereof
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
WO2018167119A1 (en) 2017-03-15 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm
CN111194221A (zh) * 2017-05-10 2020-05-22 威斯塔解剖学和生物学研究所 优化的核酸抗体构建体
ES2911600T3 (es) 2017-06-20 2022-05-20 Inst Nat Sante Rech Med Métodos para identificar si pacientes con insuficiencia cardiaca aguda descompensada (ICAD) presentan un estado hipercoagulable
CN107299112A (zh) * 2017-06-22 2017-10-27 广东药科大学 一种炎症分子（psgl‑1）缺失的脂代谢异常模型的构建及其应用
WO2019025847A1 (en) 2017-08-04 2019-02-07 Novartis Ag TREATMENT DIAGRAMS
EP3762424A1 (en) 2018-03-08 2021-01-13 Novartis AG Use of an anti-p-selectin antibody
AU2020289364A1 (en) 2019-06-07 2022-01-06 Novartis Ag Use of an anti-P-selectin antibody
EP3790545A4 (en) 2019-07-17 2021-07-28 Emmaus Medical, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF SICKLE CLEANEMIA AND THALASSEMIA
WO2021087050A1 (en) 2019-10-30 2021-05-06 Novartis Ag Crizanlizumab containing antibody formulation
WO2021116789A1 (en) 2019-12-09 2021-06-17 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
EP4077676A1 (en) 2019-12-18 2022-10-26 Novartis AG Compositions and methods for the treatment of hemoglobinopathies
WO2022269518A2 (en) 2021-06-23 2022-12-29 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
DK0606391T3 (da) 1991-09-30 1999-05-03 Biogen Inc Inhibering af karforsnævring under anvendelse af anti-PADGEM-antistoffer
ES2152251T3 (es) 1992-04-30 2001-02-01 Genentech Inc Variantes del dominio lectina de la selectina.
US6033667A (en) 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
DK0642356T3 (da) * 1992-05-05 2003-08-04 Aeres Biomedical Ltd Antistoffer mod P-selectin og deres anvendelser
EP0804235A4 (en) 1993-05-04 2001-09-19 Aeres Biomedical Ltd ANTIBODIES AGAINST SELECTIN P AND USES THEREOF
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH10504527A (ja) 1994-06-03 1998-05-06 センター・フォー・ブラッド・リサーチ・インコーポレーテッド アテローム性動脈硬化の治療法および防止法
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
ATE512225T1 (de) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
EP1289552B1 (en) 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003230985A1 (en) * 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
EP2301966A1 (en) 2002-12-16 2011-03-30 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
EP2097105A4 (en) 2006-12-01 2010-09-15 Selexys Pharmaceuticals Corp ANTI-P-SELECTINE ANTIBODIES AND METHODS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US20110212096A1 (en) * 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
JP2011524858A (ja) 2008-05-15 2011-09-08 セレクシーズ ファーマスーティカルズ コーポレーション 抗ｐｓｇｌ−１抗体並びにその同定及び使用方法
HUE037992T2 (hu) 2010-12-21 2018-09-28 Selexys Pharmaceuticals Corp Anti-P-szelektin antitestek és eljárások azok alkalmazására és azonosítására

Also Published As

Publication number Publication date
PT2662091T (pt) 2018-12-03
LT2662091T (lt) 2018-12-10
LTPA2021506I1 (lt) 2021-05-10
US8377440B2 (en) 2013-02-19
CY2021009I1 (el) 2021-10-15
EP3501538A1 (en) 2019-06-26
SI2662091T1 (sl) 2019-01-31
US20140072551A1 (en) 2014-03-13
EP2662091A2 (en) 2013-11-13
EP2097105A4 (en) 2010-09-15
WO2008069999A3 (en) 2008-12-04
CY1121072T1 (el) 2019-12-11
EP2662091B1 (en) 2018-08-22
DK2662091T3 (en) 2018-12-17
US20110243926A1 (en) 2011-10-06
US9556266B2 (en) 2017-01-31
HUS2100015I1 (hu) 2021-05-28
LTC2662091I2 (lt) 2022-10-10
EP2662091A3 (en) 2014-03-12
ES2699273T3 (es) 2019-02-08
HUE041957T2 (hu) 2019-06-28
EP2097105A2 (en) 2009-09-09
PL2662091T3 (pl) 2019-05-31
WO2008069999A2 (en) 2008-06-12
CY2021009I2 (el) 2021-12-31

Similar Documents

Publication Publication Date Title
HUS2100015I1 (hu) Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
IL248723B (en) Specific antibodies against the bcr complex and methods of using them
HK1223114A1 (zh) 抗因子 單克隆抗體及其使用方法
ZA200903775B (en) Human monoclonal antibodies to BTLA and methods of use
HK1141811A1 (en) Human antibodies to human cd20 and method of using thereof cd20
EP2086583A4 (en) FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USE
EP2212432A4 (en) COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
EP2315780B8 (en) Compositions and methods of use for therapeutic antibodies
EP2373691A4 (en) ANTI-FXI ANTIBODIES AND METHOD FOR THEIR USE
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
IL196920A0 (en) Compositions and methods using anti-csi antibodies to treat multiple myeloma
EP2195025A4 (en) THERAPEUTIC ANTIBODY PURIFICATION METHOD AND METHOD OF USE
IL232011A0 (en) Antibodies to 7egfl and methods of using them
SI2068930T1 (sl) Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma
ZA200807225B (en) Antibodies to EGFL7 and methods for their use
IL202502A0 (en) Agents for the treatment of inflammatory diseases and methods of using same